Abstract

Medtronic PLC will report quarterly results on September 1, 2026 Pre-MKt; this preview summarizes expected revenue, profit metrics, adjusted EPS, business mix, the likely impact of newly closed acquisitions and legal developments, and how prevailing analyst sentiment could influence trading into and after the print.

Market Forecast

Current-quarter forecasts point to revenue of 9.54 billion US dollars, up 13.93% year over year, adjusted EPS of 1.39, up 12.90% year over year, and EBIT of 2.26 billion US dollars, up 14.06% year over year. Forecasts did not disclose gross profit margin or net profit margin for the quarter. Last quarter’s business mix sets the context for the quarter under review: Cardiac and Vascular generated 3.80 billion US dollars, Neuroscience 2.75 billion US dollars, Medical Surgical 2.39 billion US dollars, and Diabetes 837.00 million US dollars, with current-quarter performance hinging on procedure volumes, product supply cadence, and integration of recently acquired neurovascular and pain assets. Among these, Neuroscience appears the most promising near-term growth opportunity given portfolio additions and workflow integration; the segment contributed 2.75 billion US dollars last quarter, while segment-level year-over-year growth was not disclosed.

Last Quarter Review

Medtronic PLC delivered revenue of 9.81 billion US dollars, a gross profit margin of 65.36%, GAAP net profit attributable to shareholders of 1.24 billion US dollars, a net profit margin of 12.68%, and adjusted EPS of 1.55, with revenue up 9.86% year over year and adjusted EPS down 4.32% year over year. A key financial highlight was sequential profit momentum, with GAAP net profit rising 8.84% quarter over quarter, aided by operating scale and stable mix. Main business highlights showed a broad-based contribution across the portfolio: Cardiac and Vascular delivered 3.80 billion US dollars, Neuroscience 2.75 billion US dollars, Medical Surgical 2.39 billion US dollars, and Diabetes 837.00 million US dollars; overall company revenue grew 9.86% year over year, supported by steady procedure volumes and continued demand for core therapies.

Current Quarter Outlook

Main revenue engine: Cardiac and Vascular

Cardiac and Vascular remains the largest contributor to group revenue, positioning this franchise as the pivotal determinant of top-line and margin outcomes this quarter. The growth algorithm for the period relies on steady underlying implant and procedure volumes, the pace of new technology adoption across electrophysiology, and dependable product availability into hospitals globally. Recent investments in intravascular and intracardiac imaging catheter capabilities are designed to support procedural efficiency and pull-through across the electrophysiology ecosystem, which, if reflected in ordering patterns, would enhance both revenue conversion and mix. With forecasts calling for total company revenue growth of 13.93%, upside versus expectations in Cardiac and Vascular would most directly influence consolidated results given the segment’s 3.80 billion US dollars contribution last quarter. Mix matters for profitability: higher-complexity therapies and procedure-enabling tools typically support better pricing and can help defend gross margin even as costs fluctuate. A steadier supply environment and stable pricing discipline would help keep gross profit margin near recent levels, while incremental efficiencies could flow through to EBIT, which is forecast at 2.26 billion US dollars this quarter, up 14.06% year over year. Beyond volumes, watch capital equipment placements and related consumables tie-in, as these can create multi-quarter revenue visibility. Any commentary on hospital budget execution, tender cadence outside the United States, or channel inventory normalization will be important tells for second-half momentum. Management’s color on product cycle progression in arrhythmia solutions and structural interventions will also shape expectations into the next quarter.

Most promising contributor: Neuroscience following portfolio additions

Neuroscience stands out as the highest-potential near-term growth contributor given portfolio expansion and workflow integration. The recent completion of the Scientia Vascular acquisition adds complementary guidewires and access technologies aimed at simplifying complex neurovascular procedures, improving navigability, and supporting faster, more reliable access to treatment sites. These access solutions integrate with existing neurovascular therapies, increasing the ability to serve physicians across the full procedural workflow and potentially strengthening pull-through of Medtronic PLC’s broader suite. The segment’s 2.75 billion US dollars last-quarter contribution sets a high base; incremental gains will hinge on cross-selling, channel education, and execution on hospital value propositions that emphasize procedural efficiency and outcomes. Integration progress tends to be visible in order patterns for access products and in attachment rates for advanced therapies; an improving attachment rate would be a positive sign that expected portfolio synergies are materializing. While segment-level year-over-year growth was not disclosed, the qualitative setup—new products, workflow simplification, and procedural growth—supports the view that Neuroscience can outgrow the consolidated average over the next few quarters if execution stays on track. In parallel, the company’s steps to diversify within neuroscience-adjacent care, including additions in pain management, aim to build exposure to durable procedure volumes and recurring utilization. Near-term, investors will focus on the pace of integration, early revenue contribution, and any comments on compatibility across product lines that could accelerate adoption. Clear evidence of cross-portfolio synergies would increase confidence in sustaining high-single-digit to low-double-digit growth within this segment relative to the consolidated outlook.

What will swing the stock: margin mix, legal developments, integration pace

Adjusted EPS is forecast at 1.39, up 12.90% year over year, and investors will parse the bridge from gross profit to EBIT to confirm operating leverage consistent with the 14.06% year-over-year EBIT outlook. A higher mix of advanced therapies and procedure-enabling technologies typically supports gross profit stability, which, combined with disciplined spending, would reinforce EPS delivery at or above expectations. Conversely, cost inflation or unfavorable mix could offset revenue upside; detailed commentary on cost of goods sold, logistics, and procurement will therefore matter for how the market extrapolates second-half margins. Legal items have emerged as a watchpoint. A recent jury verdict involving a legacy product line resulted in an 88.00 million US dollars award in a hernia patch case, and risk disclosures have highlighted the potential for broader legal liabilities to affect financial performance. While the near-term P&L impact from such matters can be episodic, investor attention will center on whether management quantifies reserves, outlines an appeals path, or frames how any cash outlay interacts with capital allocation priorities. Clarity here would reduce uncertainty that can compress the multiple, even if the fundamental operating trend remains intact. Finally, integration cadence for newly acquired assets is a potential upside lever. Neuroscience access technologies from Scientia Vascular and additions in pain management aim to expand the addressable opportunity and improve continuity of care. The near-term questions are practical: how quickly hospital committees approve integrated solutions, how soon field teams translate portfolio breadth into ordering momentum, and whether initial post-close sales trends align with internal plans. Clear evidence of early cross-selling and stable gross-to-net dynamics would strengthen the case that the current-quarter revenue forecast of 9.54 billion US dollars is achievable with room for favorable variance.

Analyst Opinions

The balance of recent published views is clearly bullish, with major institutions reiterating or upgrading positive stances and higher target prices outnumbering neutral or cautious notes. Wells Fargo has maintained Buy ratings across multiple updates, most recently setting targets at 102.00 US dollars in late summer commentaries; the analyst team emphasizes a favorable setup into upcoming results and continued execution in core franchises. UBS upgraded the shares to Buy with a 100.00 US dollars target, citing a constructive view on product-cycle support and a belief that the shares can close a valuation gap as new technologies contribute to growth. TD Cowen reiterated a Buy rating with a 119.00 US dollars target, highlighting sustained progress in portfolio initiatives and confidence in earnings durability. Evercore ISI reiterated Buy with a 106.00 US dollars target, framing the quarter as an opportunity to validate improving growth and margin trajectory. Neutral stances exist but are not the majority; Piper Sandler and J.P. Morgan have reaffirmed Hold views at various points, typically underscoring a wait-and-see approach on execution and the magnitude of upside relative to valuation. Across the collected notes during the recent six-month window, bullish opinions outweigh bearish views by a wide margin, with positive calls from Wells Fargo, UBS, TD Cowen, and Evercore ISI setting the tone. What matters for this print, according to the bullish cohort, is confirmation of three pillars: delivery against the 9.54 billion US dollars revenue forecast and 1.39 adjusted EPS trajectory; margin stewardship that demonstrates operating leverage consistent with the 2.26 billion US dollars EBIT outlook; and tangible signals that portfolio adjacency moves—particularly in neurovascular access and pain management—are beginning to translate into commercial momentum. Positive reads on these pillars would, in their view, justify upward revisions to out-quarter models and support a constructive rerating. The institutional consensus also flags that clarity on legal exposures and the cadence of integration milestones can reduce headline risk, enabling fundamentals to dominate the narrative into subsequent quarters. In sum, the majority institutional perspective anticipates a solid quarter characterized by double-digit revenue and earnings growth on a year-over-year basis, steady profitability, and early contributions from recent business development activity. Should management affirm this trajectory on September 1, 2026 Pre-MKt while providing incremental detail on legal and integration dynamics, bulls expect the shares to respond favorably as confidence builds in the sustainability of the current growth arc.